Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...
RXRX remains down by 35% year-to-date and is trading below $5. Thus, the critical question isn’t about a single good ...
Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...
'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after viewing boat strike video: Democrat calls it 'one of the most troubling ...
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been ...
And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...
The simulation hypothesis — the idea that our universe might be an artificial construct running on some advanced alien ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
Skills—a capability that allows users to teach Claude repeatable workflows—was introduced in October, and now Anthropic is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results